Advanced or metastatic non-small cell lung cancer (NSCLC) harbouring an NTRK1, NTRK2, or NTRK3 gene fusion is a distinct, actionable molecular subtype. Confirming the fusion by molecular testing is the critical step that defines first-line treatment selection for this population.
NTRK1/2/3 gene fusions are rare in NSCLC, estimated to occur in fewer than 1% of patients, and do not typically co-occur with other known oncogenic drivers. This low prevalence makes systematic molecular testing essential to identify eligible patients.
For patients with confirmed NTRK gene fusion-positive advanced or metastatic NSCLC, current evidence supports a first-line targeted therapy strategy. Preferred agents and the criteria governing their selection are detailed in the full protocol.
It is estimated that NTRK1/2/3 gene fusions occur in <1% of patients with NSCLC and do not typically overlap with other known oncogenic drivers.
The Panel recommends entrectinib, larotrectinib, or repotrectinib as preferred first-line therapy options for patients with NTRK1/2/3 gene fusion-positive advanced or metastatic NSCLC (PS 0–4).
View source ↗